Differential toxicity of ataxin-3 isoforms in Drosophila models of Spinocerebellar Ataxia Type 3.


Journal

Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169

Informations de publication

Date de publication:
12 2019
Historique:
received: 04 06 2019
revised: 05 07 2019
accepted: 12 07 2019
pubmed: 17 7 2019
medline: 28 7 2020
entrez: 17 7 2019
Statut: ppublish

Résumé

The most commonly inherited dominant ataxia, Spinocerebellar Ataxia Type 3 (SCA3), is caused by a CAG repeat expansion that encodes an abnormally long polyglutamine (polyQ) repeat in the disease protein ataxin-3, a deubiquitinase. Two major full-length isoforms of ataxin-3 exist, both of which contain the same N-terminal portion and polyQ repeat, but differ in their C-termini; one (denoted here as isoform 1) contains a motif that binds ataxin-3's substrate, ubiquitin, whereas the other (denoted here as isoform 2) has a hydrophobic tail. Most SCA3 studies have focused on isoform 1, the predominant version in mammalian brain, yet both isoforms are present in brain and a better understanding of their relative pathogenicity in vivo is needed. We took advantage of the fruit fly, Drosophila melanogaster to model SCA3 and to examine the toxicity of each ataxin-3 isoform. Our assays reveal isoform 1 to be markedly more toxic than isoform 2 in all fly tissues. Reduced toxicity from isoform 2 is due to much lower protein levels as a result of its expedited degradation. Additional studies indicate that isoform 1 is more aggregation-prone than isoform 2 and that the C-terminus of isoform 2 is critical for its enhanced proteasomal degradation. According to our results, although both full-length, pathogenic ataxin-3 isoforms are toxic, isoform 1 is likely the primary contributor to SCA3 due to its presence at higher levels. Isoform 2, as a result of rapid degradation that is dictated by its tail, is unlikely to be a key player in this disease. Our findings provide new insight into the biology of this ataxia and the cellular processing of the underlying disease protein.

Identifiants

pubmed: 31310802
pii: S0969-9961(19)30203-7
doi: 10.1016/j.nbd.2019.104535
pmc: PMC6834911
mid: NIHMS1538510
pii:
doi:

Substances chimiques

Drosophila Proteins 0
Protein Isoforms 0
Repressor Proteins 0
ATXN3 protein, human EC 3.4.19.12
Ataxin-3 EC 3.4.19.12

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104535

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS038712
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS086778
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS104326
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Annu Rev Pathol. 2019 Jan 24;14:1-27
pubmed: 30089230
Neuromolecular Med. 2011 Mar;13(1):54-65
pubmed: 20945165
Anal Biochem. 2008 Feb 15;373(2):330-6
pubmed: 17949677
J Neurosci. 2007 Jul 11;27(28):7418-28
pubmed: 17626202
J Biol Chem. 2005 Feb 4;280(5):3898-910
pubmed: 15533937
Prog Neurobiol. 2011 Sep 15;95(1):26-48
pubmed: 21740957
Hum Mol Genet. 2015 Aug 1;24(15):4385-96
pubmed: 25954029
Genetics. 2004 Apr;166(4):1775-82
pubmed: 15126397
Nucleic Acids Res. 2003 Oct 1;31(19):5469-82
pubmed: 14500809
Neurogenetics. 2010 May;11(2):193-202
pubmed: 19714377
Nat Struct Mol Biol. 2013 Jan;20(1):59-66
pubmed: 23202584
Aging (Albany NY). 2015 Aug;7(8):535-52
pubmed: 26298685
J Hum Genet. 2001;46(7):413-22
pubmed: 11450850
Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):358-366
pubmed: 30622213
Ann Neurol. 1997 Apr;41(4):453-62
pubmed: 9124802
Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):191-5
pubmed: 12218651
Hum Mol Genet. 2011 Dec 15;20(24):4810-21
pubmed: 21933837
J Biol Chem. 2005 Sep 9;280(36):32026-34
pubmed: 16040601
J Biol Chem. 2017 Jun 9;292(23):9493-9504
pubmed: 28442575
Neurosci Res. 1997 Aug;28(4):373-7
pubmed: 9274833
Curr Biol. 2005 May 10;15(9):862-8
pubmed: 15886106
Cell. 2005 May 20;121(4):553-565
pubmed: 15907469
Nature. 2008 Jun 19;453(7198):1107-11
pubmed: 18449188
J Biol Chem. 2010 Dec 10;285(50):39303-13
pubmed: 20943656
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12602-7
pubmed: 11675496
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4604-9
pubmed: 10200309
J Biol Chem. 2019 Jan 11;294(2):644-661
pubmed: 30455355
Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):260-5
pubmed: 21173221
Hum Mol Genet. 2017 Apr 15;26(8):1419-1431
pubmed: 28158474
J Biol Chem. 2007 Oct 5;282(40):29348-58
pubmed: 17693639
J Huntingtons Dis. 2013;2(2):201-15
pubmed: 24683430
Neuron. 2003 Jun 5;38(5):681-4
pubmed: 12797953
PLoS One. 2008 May 07;3(5):e2115
pubmed: 18461180
Neuropathology. 2018 Apr;38(2):113-124
pubmed: 29218765
Annu Rev Neurosci. 2000;23:217-47
pubmed: 10845064
Neuron. 1997 Aug;19(2):333-44
pubmed: 9292723
Biochim Biophys Acta. 2004 Nov 29;1695(1-3):189-207
pubmed: 15571815
Nature. 2017 May 4;545(7652):108-111
pubmed: 28445460
Neurobiol Dis. 2018 Aug;116:78-92
pubmed: 29704548
J Biol Chem. 2013 Nov 29;288(48):34460-9
pubmed: 24106274
Genetics. 2004 Nov;168(3):1337-52
pubmed: 15579689
J Biol Chem. 2012 Apr 27;287(18):14659-71
pubmed: 22318722
Genes Dev. 2010 Mar 1;24(5):438-42
pubmed: 20194437
J Biol Chem. 2009 Mar 20;284(12):7425-9
pubmed: 18957430
Cell. 1998 Feb 6;92(3):367-80
pubmed: 9476896
Brain Pathol. 1998 Oct;8(4):669-79
pubmed: 9804376
Brain. 2016 Nov 1;139(11):2891-2908
pubmed: 27645800
Neurotherapeutics. 2019 Apr;16(2):263-286
pubmed: 30607747
J Neurochem. 2019 Jan;148(1):8-28
pubmed: 29959858
Neuron. 2015 Nov 18;88(4):667-77
pubmed: 26590344
J Mol Biol. 2015 Aug 28;427(17):2748-56
pubmed: 26191773
J Biol Chem. 2008 Sep 26;283(39):26436-43
pubmed: 18599482
Antioxid Redox Signal. 2014 Jan 20;20(3):460-73
pubmed: 23725295
Nat Commun. 2014 Aug 21;5:4638
pubmed: 25144244
Mol Cell. 2005 Apr 1;18(1):37-48
pubmed: 15808507
Dev Biol. 2010 Sep 15;345(2):117-32
pubmed: 20599890
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14870-5
pubmed: 22927375
PLoS One. 2010 Oct 27;5(10):e13695
pubmed: 21060878
Neurobiol Dis. 2015 Oct;82:12-21
pubmed: 26007638
Cell. 1997 Aug 8;90(3):549-58
pubmed: 9267034
Development. 1993 Jun;118(2):401-15
pubmed: 8223268
Genetics. 2008 Jan;178(1):215-34
pubmed: 18202369
Cold Spring Harb Perspect Biol. 2018 Dec 3;10(12):
pubmed: 29891563
Adv Exp Med Biol. 2018;1049:349-367
pubmed: 29427113
Biochem Biophys Res Commun. 2007 Oct 26;362(3):734-9
pubmed: 17764659
Hum Mol Genet. 2012 May 15;21(10):2211-8
pubmed: 22337953
EMBO J. 2009 Feb 18;28(4):372-82
pubmed: 19153604
Brain Res. 2016 Sep 15;1647:30-42
pubmed: 27060770
Sci Rep. 2018 May 31;8(1):8513
pubmed: 29855490
Nat Genet. 1994 Nov;8(3):221-8
pubmed: 7874163
Int J Mol Sci. 2015 Aug 11;16(8):18741-51
pubmed: 26270660
Biol Open. 2016 Dec 15;5(12):1770-1775
pubmed: 27979829
Brain Pathol. 2016 Nov;26(6):779-786
pubmed: 27529325
Nat Rev Neurosci. 2017 Oct;18(10):613-626
pubmed: 28855740
Prog Neurobiol. 2012 May;97(2):239-57
pubmed: 22133674

Auteurs

Sean L Johnson (SL)

Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA.

Jessica R Blount (JR)

Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA.

Kozeta Libohova (K)

Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA.

Bedri Ranxhi (B)

Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA.

Henry L Paulson (HL)

Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.

Wei-Ling Tsou (WL)

Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA. Electronic address: wtsou@wayne.edu.

Sokol V Todi (SV)

Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA; Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA. Electronic address: stodi@wayne.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH